Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary
暂无分享,去创建一个
R. Pazdur | Todd R. Palmby | Lijun Zhang | R. Justice | R. Sridhara | Shenghui Tang | A. Ibrahim | P. Kluetz | N. Mehrotra | A. Tilley | E. Pfuma | Debasis Ghosh | R. Aziz | V. E. Maher | J. F. Zirkelbach | Y. Ning | Amy Tilley
[1] S. Balk,et al. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis , 2014, Oncogene.
[2] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[3] W. Oh,et al. Targeting the androgen receptor signalling axis in castration‐resistant prostate cancer (CRPC) , 2012, BJU international.
[4] F. Saad,et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.
[5] M. Dowsett,et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. , 2012, The Journal of clinical endocrinology and metabolism.
[6] E. Small,et al. Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response , 2011, Clinical Cancer Research.
[7] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[8] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.
[9] E. Basch,et al. The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. , 2010, Pain medicine.
[10] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[12] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[13] B. Freidlin,et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] N. Dawson,et al. The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints. , 1997, European journal of cancer.
[15] Ian Kenning,et al. Disclosure of Potential Conflicts of Interest , 2014 .
[16] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[17] J. R. Scotti,et al. Available From , 1973 .